teaser
Teva UK Limited has signalled its commitment to developing biosimilar medicines by entering the G-CSF therapy area.
The launch of its proprietary version of filgrastim, TevaGrastim, marks the Company’s first biosimilar, and represents a major addition to Teva’s Hospitals portfolio.
TevaGrastim is licenced for a number of indications, the most common being the reduction of chemotherapy-induced neutropenia. The product is available in two presentations, both are available from wholesalers, ie, 30 MIU pre-filled syringe (5 pack) and 48 MIU pre-filled syringe (5 pack).
TevaGrastim is licensed for the same indications as the reference product, Neupogen (filgrastim). Teva’s pre-filled syringe will also incorporate a needle guard to minimise the risk of needle stick injuries.
When comparing NHS list prices of filgrastim products, TevaGrastim is a competitively priced G-CSF treatment.
